Publication: Modulated expression of the HIV-1 2LTR zinc finger efficiently interferes with the HIV integration process
| dc.contributor.author | Moonmuang S. | |
| dc.contributor.author | Saoin S. | |
| dc.contributor.author | Chupradit K. | |
| dc.contributor.author | Sakkhachornphop S. | |
| dc.contributor.author | Israsena N. | |
| dc.contributor.author | Rungsiwiwut R. | |
| dc.contributor.author | Tayapiwatana C. | |
| dc.date.accessioned | 2021-04-05T03:05:37Z | |
| dc.date.available | 2021-04-05T03:05:37Z | |
| dc.date.issued | 2018 | |
| dc.date.issuedBE | 2561 | |
| dc.description.abstract | Lentiviral vectors have emerged as the most efficient system to stably transfer and insert genes into cells. By adding a tetracycline (Tet)-inducible promoter, transgene expression delivered by a lentiviral vector can be expressed whenever needed and halted when necessary. Here we have constructed a doxycycline (Dox)-inducible lentiviral vector which efficiently introduces a designed zinc finger protein, 2-long terminal repeat zinc-finger protein (2LTRZFP), into hematopoietic cell lines and evaluated its expression in pluripotent stem cells. As a result this lentiviral inducible system can regulate 2LTRZFP expression in the SupT1 T-cell line and in pluripotent stem cells. Using this vector, no basal expression was detected in the T-cell line and its induction was achieved with low Dox concentrations. Remarkably, the intracellular regulatory expression of 2LTRZFP significantly inhibited HIV-1 integration and replication in HIV-inoculated SupT1 cells. This approach could provide a potential tool for gene therapy applications, which efficiently control and reduce the side effect of therapeutic genes expression. © 2018 The Author(s). | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.citation | Bioscience Reports. Vol 38, No.5 (2018) | |
| dc.identifier.doi | 10.1042/BSR20181109 | |
| dc.identifier.issn | 1448463 | |
| dc.identifier.other | 2-s2.0-85052957177 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14740/5852 | |
| dc.rights.holder | Scopus | |
| dc.subject.other | Doxycycline | |
| dc.subject.other | Lentivirus vector | |
| dc.subject.other | Protein 2LTR | |
| dc.subject.other | Tetracycline | |
| dc.subject.other | Unclassified drug | |
| dc.subject.other | Zinc finger protein | |
| dc.subject.other | Doxycycline | |
| dc.subject.other | Tetracycline | |
| dc.subject.other | Zinc finger protein | |
| dc.subject.other | Antiviral activity | |
| dc.subject.other | Article | |
| dc.subject.other | Controlled study | |
| dc.subject.other | Gene expression | |
| dc.subject.other | Gene therapy | |
| dc.subject.other | Hematopoietic cell line | |
| dc.subject.other | Human immunodeficiency virus 1 infection | |
| dc.subject.other | Nonhuman | |
| dc.subject.other | Pluripotent stem cell | |
| dc.subject.other | Protein expression | |
| dc.subject.other | Protein stability | |
| dc.subject.other | SUP-T1 cell line | |
| dc.subject.other | T lymphocyte | |
| dc.subject.other | Therapy effect | |
| dc.subject.other | Virus DNA cell DNA interaction | |
| dc.subject.other | Virus induction | |
| dc.subject.other | Virus interference | |
| dc.subject.other | Virus replication | |
| dc.subject.other | Dose response | |
| dc.subject.other | Drug effect | |
| dc.subject.other | Gene expression regulation | |
| dc.subject.other | Gene vector | |
| dc.subject.other | Genetics | |
| dc.subject.other | HEK293 cell line | |
| dc.subject.other | Human | |
| dc.subject.other | Human immunodeficiency virus 1 | |
| dc.subject.other | Human immunodeficiency virus infection | |
| dc.subject.other | Lentivirus | |
| dc.subject.other | Long terminal repeat | |
| dc.subject.other | Pathogenicity | |
| dc.subject.other | Physiology | |
| dc.subject.other | Procedures | |
| dc.subject.other | Transgene | |
| dc.subject.other | Virology | |
| dc.subject.other | Virus DNA cell DNA interaction | |
| dc.subject.other | Dose-Response Relationship, Drug | |
| dc.subject.other | Doxycycline | |
| dc.subject.other | Gene Expression Regulation | |
| dc.subject.other | Genetic Therapy | |
| dc.subject.other | Genetic Vectors | |
| dc.subject.other | HEK293 Cells | |
| dc.subject.other | HIV Infections | |
| dc.subject.other | HIV Long Terminal Repeat | |
| dc.subject.other | HIV-1 | |
| dc.subject.other | Humans | |
| dc.subject.other | Lentivirus | |
| dc.subject.other | Pluripotent Stem Cells | |
| dc.subject.other | Tetracycline | |
| dc.subject.other | Transgenes | |
| dc.subject.other | Virus Integration | |
| dc.subject.other | Zinc Fingers | |
| dc.title | Modulated expression of the HIV-1 2LTR zinc finger efficiently interferes with the HIV integration process | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| swu.datasource.scopus | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052957177&doi=10.1042%2fBSR20181109&partnerID=40&md5=bca53f2880a16d21efb8f71e053657a0 |
